Hot Features
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningit... CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 2.6 | 2.6 | 2.6 | 200 | 2.6 | CS |
| 4 | -0.26 | -9.09090909091 | 2.86 | 2.86 | 2.6 | 133 | 2.665 | CS |
| 12 | -1.26 | -32.6424870466 | 3.86 | 4 | 2.6 | 436 | 3.48577982 | CS |
| 26 | -2.145 | -45.2054794521 | 4.745 | 4.745 | 2.6 | 371 | 3.66320498 | CS |
| 52 | -2.4 | -48 | 5 | 6.99 | 2.6 | 1494 | 4.38147055 | CS |
| 156 | -0.9 | -25.7142857143 | 3.5 | 6.99 | 1.86 | 1848 | 3.38157845 | CS |
| 260 | -38.19 | -93.6258886982 | 40.79 | 49.02 | 1.86 | 2319 | 15.31132774 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.